Fluvoxamine is an antidepressant and a selective serotonin reuptake inhibitor. The National Institutes of Health undertook a research study to see if Fluvoxamine could be given early in the course of a COVID-19 infection to prevent more significant problems including shortness of breath. It inhibited the generation of inflammatory cytokines in a mouse sepsis model and in human endothelial cells in vitro. The expression of inflammatory genes was lowered in human endothelium, yielding similar outcomes. According to the National Health Institute, it was not approved for usage due to a lack of evidence in clinical research.

Referencing

Godman, B., Kurdi, A., McCabe, H., Johnson, C.F., Barbui, C., MacBride-Stewart, S., Hurding, S., Leporowski, A., Bennie, M. and Morton, A., 2019. Ongoing initiatives within the Scottish National Health Service to affect the prescribing of selective serotonin reuptake inhibitors and their influence. Journal of comparative effectiveness research, 8(7), pp.535-547.